KZR
NASDAQ · Biotechnology
Kezar Life Sciences Inc
$6.12
+0.09 (+1.49%)
Open$6.03
Previous Close$6.03
Day High$6.15
Day Low$6.03
52W High$18.07
52W Low$12.93
Volume—
Avg Volume161.4K
Market Cap44.82M
P/E Ratio35.82
EPS$0.41
SectorBiotechnology
Analyst Ratings
Hold
10 analysts
Price Target
+207.4% upside
Current
$6.12
$6.12
Target
$18.81
$18.81
$12.87
$18.81 avg
$22.25
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 16.79M | 17.27M | 15.12M |
| Net Income | 1.29M | 1.30M | 1.12M |
| Profit Margin | 7.7% | 7.5% | 7.4% |
| EBITDA | 2.04M | 2.03M | 1.93M |
| Free Cash Flow | 959.0K | 942.1K | 1.29M |
| Rev Growth | +17.9% | +7.1% | +16.0% |
| Debt/Equity | 0.82 | 0.90 | 0.98 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |